Developer docs
API playgroundTry for free, no card

Search company profiles

vVardis

Full company profile

uuid0000ges

Namestring
vVardis
Legal namestring
vVARDIS AG
Websiteurl
vvardis.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

vVardis is a privately held Swiss dental medtech company founded in 2020 in Baar, Switzerland, by sisters and co-CEOs Dr. Haley Abivardi, DMD, and Dr. Goly Abivardi, DMD. The company commercializes a proprietary biomimetic peptide technology (P11-4), branded Curodont™, which is the first and only chairside, drill-free, needle-free, regenerative treatment for early-stage dental caries. The P11-4 self-assembling peptide diffuses into early carious lesions, halts decay progression, and rebuilds lost enamel by attracting calcium and phosphate from saliva — addressing the historical treatment gap between preventive care and conventional drilling/filling. The technology is supported by 25+ years of underlying research, 200+ clinical studies, and 230+ peer-reviewed publications, and is progressively being integrated into the curricula of prestigious dental schools.

vVardis's commercial product line consists of Curodont Repair and the enhanced Curodont Repair Fluoride Plus, applied chairside in as little as 3 minutes (US) to ~5 minutes (EU) per lesion, typically a one-time application. Revenue is generated primarily through B2B sales of the professional product to dental practices via an exclusive U.S. distribution agreement with Henry Schein across all dental segments (effective January 2026) and a UK partnership with mydentist covering ~500 practices. A secondary, smaller revenue stream comes from direct-to-consumer e-commerce on vvardis.com for the US market, with free shipping, recurring 30-day subscription options, and a 30-day return policy. As of April 2026, Curodont has been used to treat approximately 3 million teeth in the United States and is present in nearly 20% of US general dental practices.

The company has scaled rapidly: it secured $85 million in cumulative financing from OrbiMed across 2025, achieved unicorn status with a $1B+ valuation through a strategic minority investment from Apollo Global Management in April 2026 (with founders retaining ~70% ownership), and operates localized commercial sites across 12 country markets (US, UK, Switzerland, Germany, France, Italy, Austria, Spain, Poland, Czech Republic, Finland, UAE). It has also built an AI-detection ecosystem via commercial collaborations with VideaHealth (VideaAI) and Pearl, integrating AI-driven early caries detection with Curodont treatment in a same-day workflow that has processed more than 400,000 patients. As of June 2026, vVardis is exploring a U.S. IPO with JPMorgan Chase and Goldman Sachs as advisors.

Short descriptiontext

vVardis is a Swiss dental medtech company that develops and commercializes Curodont™, a proprietary biomimetic P11-4 peptide-based drill-free treatment for early-stage tooth decay, sold to dental professionals globally through exclusive distributors and direct channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomimetic dental treatment, drill-free cavity treatment, enamel remineralization products, peptide-based dental care, preventive dental technology
Industry5 codes
PRIMARYHLABAAAC
Cosmetic & Esthetic Dentistry (Veneers/Whitening/Bonding)
SECONDARYHLABAHAJ
Non-Surgical Periodontal Therapy (Scaling & Root Planing)
Healthcare & Life Sciences/Dental Care Services/Dental Hygiene & Preventive Services
SECONDARYHLABAHAK
Desensitization Treatments for Dentin Hypersensitivity
Healthcare & Life Sciences/Dental Care Services/Dental Hygiene & Preventive Services
SECONDARYHLABACAA
Non-Surgical Periodontal Therapy (Scaling & Root Planing)
Healthcare & Life Sciences/Dental Care Services/Periodontics (Gum & Implant Services)
SECONDARYHLABAAAA
Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride)
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Dental Laboratories339116
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Dental Equipment & Supplies3843
Product category
Biomimetic Dental Care
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Dental professional / clinic product sales (via distribution partner)
TypeTransaction Fee
Description

vVARDIS generates revenue by selling its Curodont product line (including Curodont Repair and Curodont Repair Fluoride Plus) to dental professionals and clinics. Sales in the US are channeled through Henry Schein as exclusive U.S. distributor across all dental segments (including DSOs). Pricing at the patient level in the UK is from £140 per course.

in.investing.com
2Direct e-commerce sales of consumer oral care products
TypeOne Time License
Description

vVARDIS operates a consumer-facing website (vvardis.com) with web shop where it sells oral care products directly to consumers with free shipping within the 50 US states, recurring order options (every 30 days), and 30-day return policy. Payment methods include Visa, MasterCard, American Express, Discover, PayPal and Apple Pay.

vvardis.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1Curodont Repair at mydentist (UK) — from £140 per course
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Priced from £140 per course across mydentist's network of ~500 UK dental practices, with rollout to 100 practices from November 2025 and full network rollout from 2026.

dentistry.co.uk
2Direct-to-consumer web shop on vvardis.com (US shipping only)
ModelOtherBilling cadencePay-as-you-go
Notes

Web shop accepts Visa, MasterCard, American Express, Discover, PayPal, and Apple Pay. Free shipping within the 50 US states. Recurring orders can be set up on a 30-day delivery cycle with cancellation via account. 30-day full refund policy for unopened products.

vvardis.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Curodont
Description

vVARDIS's proprietary biomimetic, peptide-based (P11-4) drill-free, needle-free dental treatment for early-stage tooth decay; includes Curodont Repair and Curodont Repair Fluoride Plus variants.

businesswire.com
+1 more record
Core offering1 text field

vVARDIS develops and commercializes its proprietary P11-4 biomimetic self-assembling peptide technology as the Curodont™ drill-free, needle-free chairside treatment for early-stage tooth decay. The peptide diffuses into early carious lesions, halts decay progression, and regenerates enamel by attracting calcium and phosphate from saliva — without drilling, anesthesia, or traditional filling materials. Products (Curodont Repair and Curodont Repair Fluoride Plus) are sold to dental professionals through Henry Schein (exclusive U.S. distributor) and channel partners, and oral care products are sold directly to consumers via vvardis.com.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • ~3 million teeth treated in the US since launch; ~20% of US general dental practices have adopted Curodont (April 2026)
+7 more records
Product overview1 text field

vVARDIS offers a single core technology platform — its proprietary P11-4 biomimetic peptide technology — which is commercialized through a unified product brand, Curodont™, comprising the chairside treatment Curodont Repair and the enhanced variant Curodont Repair Fluoride Plus. The Curodont family is the drill-free, needle-free treatment for early-stage dental caries and is delivered to dental professionals through the vVARDIS Professional program and the Certified Curodontist™ certification, supported by the "Save Teeth Save Lives" global awareness campaign. Together these elements form an integrated non-invasive dental-care platform rather than a set of unrelated products.

Product and service2 records
1Curodont Repair
CategoryDrill-free chairside dental treatment
Description

Chairside drill-free, needle-free treatment for early-stage tooth decay (caries) based on vVARDIS's proprietary P11-4 biomimetic self-assembling peptide. The peptide diffuses into early carious lesions, halts decay progression, and regenerates lost enamel minerals by attracting calcium and phosphate from saliva — without anesthesia, drilling, or traditional filling materials. Applied by dental professionals in as little as 3–10 minutes; suitable for children and adults.

2Curodont Repair Fluoride Plus
CategoryDrill-free chairside dental treatment (fluoride-enhanced)
Description

Enhanced chairside drill-free treatment combining vVARDIS's P11-4 biomimetic peptide technology with fluoride for early caries management. Used in same-day workflows following AI-powered caries detection by VideaHealth, with over 400,000 patients identified and treated with a 90%+ success rate. Sold to dental professionals in the US exclusively through Henry Schein across all dental segments including DSOs.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagship / CoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-01
Description

Expanded partnership (announced December 1, 2025) makes Henry Schein the exclusive U.S. distributor of Curodont Repair Fluoride Plus across all U.S. dental segments starting January 1, 2026. Henry Schein had previously been named exclusive distributor to larger DSOs in September 2024. Henry Schein, Inc. is publicly traded on Nasdaq (HSIC), valued at approximately $9B with $12.7B in 2024 sales.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-01
Description

First-of-its-kind partnership in UK dentistry announced January 2026 covering mydentist's network of ~500 practices; Curodont Repair offered at 100 practices from November 2025 with full network rollout from 2026. Priced from £140 per course, addressing more than four million patients in mydentist's network.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-14
Description

Global collaboration announced May 14, 2025, transforming early detection and proactive treatment of early dental decay. Pearl's AI enables dental practitioners to detect tooth decay earlier, while vVARDIS Curodont offers a drill-free solution to treat early stages of tooth decay.

Strategic tierFlagship / CoreTypeTechnology or IntegrationAnnounced on2024-06-13
Description

Commercial collaboration combining VideaHealth's AI-powered dental detection (VideaAI) with vVARDIS's Curodont Repair Fluoride Plus for end-to-end early detection and drill-free treatment. Over 400,000 patients identified with early caries through VideaAI have been treated with Curodont, demonstrating 90%+ success rate in treating early caries.

5Prestigious universities and dental schools
Strategic tierCoreTypeStrategic or Co-development Partner
Description

vVARDIS partners with prestigious universities and dental professionals to advance research, support clinical studies, and progressively integrate Curodont technology into dental school curricula. The company's technology has been peer-reviewed in 230+ publications.

vvardis.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

vVARDIS products are included in the National Academy Training program focused on sustainability in dentistry, providing ESG-aligned training and education for dental professionals.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Heartland Dental (1,800+ practices across 39 states + DC) integrated advanced AI and biomimetic technologies including vVARDIS Curodont in 2024, expanding partnerships in 2025 as one of the major DSOs adopting Curodont across its supported practices.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Dentsply Sirona
TypeBroad incumbent
Description

Largest pure-play dental equipment and consumables company globally; supplies preventive and restorative materials (including fluoride, glass ionomers, and remineralization products) that compete for the same chairside minutes and DSOs as vVARDIS's Curodont. Comparable because it operates across the same dental practice and DSO buyer base, even though its biomimetic peptide exposure is limited.

TypeBroad incumbent
Description

Major dental materials and preventive care business (now part of Solventum) offering fluoride varnishes, sealants, and restorative products sold to the same U.S. dental practices and DSOs that vVARDIS targets. Comparable as a broad incumbent with overlapping preventive-care channels and the capital to bundle competing products.

TypeBroad incumbent
Description

Japanese-headquartered dental materials manufacturer whose MI Paste / Recaldent (CPP-ACP) line is a competing chairside remineralization/early-caries product. Most directly comparable incumbent on the 'non-invasive early lesion treatment' category vVARDIS competes in.

TypeEmerging player
Description

U.S. dental materials manufacturer with a strong preventive and minimally invasive portfolio (e.g., enamel-strengthening and desensitizing products) sold to the same dental professionals as Curodont. Comparable as a specialist dental materials player competing for chairside early-intervention minutes.

TypeEmerging player
Description

German dental materials company specializing in preventive and restorative products, including remineralization and sealants. Comparable to vVARDIS as a specialist competitor in early caries intervention and minimally invasive dental materials sold through professional channels.

TypeEmerging player
Description

U.S. dental materials manufacturer focused on adhesive, resin, and preventive products sold to general dentists and specialists. Comparable as a specialist dental materials company competing for chairside early-intervention share and DSO contracts.

TypeEmerging player
Description

German dental materials manufacturer with a portfolio including preventive and minimally invasive products sold to dental professionals globally. Comparable to vVARDIS in its focus on preventive/minimally invasive dentistry and DSO-relevant professional channels.

TypeEmerging player
Description

U.S. dental products company offering preventive, restorative and hygiene products to general dentists and DSOs. Comparable as a specialist dental materials company with overlapping buyer base and product categories (prevention, remineralization).

TypeEmerging player
Description

AI dental imaging company with Second Opinion / Pearl AI detection software that flags early caries on dental x-rays — a current vVARDIS commercial partner. Comparable as a participant in the AI-powered early caries detection workflow that feeds Curodont treatments.

TypeEmerging player
Description

AI dental caries detection company (VideaAI) that is a commercial partner with vVARDIS, having routed 400,000+ patients into Curodont treatment. Comparable as a participant in the same AI-detection-to-treatment workflow that drives vVARDIS's same-day chairside adoption.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

vVardis

Biomimetic Dental Carevvardis.com

vVardis is a Swiss dental medtech company that develops and commercializes Curodont™, a proprietary biomimetic P11-4 peptide-based drill-free treatment for early-stage tooth decay, sold to dental professionals globally through exclusive distributors and direct channels.

What vVardis does

vVardis is a privately held Swiss dental medtech company founded in 2020 in Baar, Switzerland, by sisters and co-CEOs Dr. Haley Abivardi, DMD, and Dr. Goly Abivardi, DMD. The company commercializes a proprietary biomimetic peptide technology (P11-4), branded Curodont™, which is the first and only chairside, drill-free, needle-free, regenerative treatment for early-stage dental caries. The P11-4 self-assembling peptide diffuses into early carious lesions, halts decay progression, and rebuilds lost enamel by attracting calcium and phosphate from saliva — addressing the historical treatment gap between preventive care and conventional drilling/filling. The technology is supported by 25+ years of underlying research, 200+ clinical studies, and 230+ peer-reviewed publications, and is progressively being integrated into the curricula of prestigious dental schools.

vVardis's commercial product line consists of Curodont Repair and the enhanced Curodont Repair Fluoride Plus, applied chairside in as little as 3 minutes (US) to ~5 minutes (EU) per lesion, typically a one-time application. Revenue is generated primarily through B2B sales of the professional product to dental practices via an exclusive U.S. distribution agreement with Henry Schein across all dental segments (effective January 2026) and a UK partnership with mydentist covering ~500 practices. A secondary, smaller revenue stream comes from direct-to-consumer e-commerce on vvardis.com for the US market, with free shipping, recurring 30-day subscription options, and a 30-day return policy. As of April 2026, Curodont has been used to treat approximately 3 million teeth in the United States and is present in nearly 20% of US general dental practices.

The company has scaled rapidly: it secured $85 million in cumulative financing from OrbiMed across 2025, achieved unicorn status with a $1B+ valuation through a strategic minority investment from Apollo Global Management in April 2026 (with founders retaining ~70% ownership), and operates localized commercial sites across 12 country markets (US, UK, Switzerland, Germany, France, Italy, Austria, Spain, Poland, Czech Republic, Finland, UAE). It has also built an AI-detection ecosystem via commercial collaborations with VideaHealth (VideaAI) and Pearl, integrating AI-driven early caries detection with Curodont treatment in a same-day workflow that has processed more than 400,000 patients. As of June 2026, vVardis is exploring a U.S. IPO with JPMorgan Chase and Goldman Sachs as advisors.

vVardis firmographics

Firmographics
Name
vVardis
Legal name
vVARDIS AG
Website
https://vvardis.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
vVardis is a Swiss dental medtech company that develops and commercializes Curodont™, a proprietary biomimetic P11-4 peptide-based drill-free treatment for early-stage tooth decay, sold to dental professionals globally through exclusive distributors and direct channels.
Ownership category
akta.pro rank

vVardis industry classification

Industry
Product category
Biomimetic Dental Care
NAICS
Dental Equipment and Supplies Manufacturing (339114), Dental Laboratories (339116)
SIC
Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)
akta.pro industry
PRIMARYHLABAAAC
Cosmetic & Esthetic Dentistry (Veneers/Whitening/Bonding)
SECONDARYHLABAHAJ
Non-Surgical Periodontal Therapy (Scaling & Root Planing)
Healthcare & Life Sciences/Dental Care Services/Dental Hygiene & Preventive Services
SECONDARYHLABAHAK
Desensitization Treatments for Dentin Hypersensitivity
Healthcare & Life Sciences/Dental Care Services/Dental Hygiene & Preventive Services
SECONDARYHLABACAA
Non-Surgical Periodontal Therapy (Scaling & Root Planing)
Healthcare & Life Sciences/Dental Care Services/Periodontics (Gum & Implant Services)
SECONDARYHLABAAAA
Preventive & Routine General Dentistry (Exams/Cleanings/Sealants/Fluoride)

Keywords

  • Biomimetic dental treatment
  • Drill-free cavity treatment
  • Enamel remineralization products
  • Peptide-based dental care
  • Preventive dental technology

Where vVardis is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices4 records

Markets served

vVardis business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Dental professional / clinic product sales (via distribution partner): vVARDIS generates revenue by selling its Curodont product line (including Curodont Repair and Curodont Repair Fluoride Plus) to dental professionals and clinics. Sales in the US are channeled through Henry Schein as exclusive U.S. distributor across all dental segments (including DSOs). Pricing at the patient level in the UK is from £140 per course.
  2. Direct e-commerce sales of consumer oral care products: vVARDIS operates a consumer-facing website (vvardis.com) with web shop where it sells oral care products directly to consumers with free shipping within the 50 US states, recurring order options (every 30 days), and 30-day return policy. Payment methods include Visa, MasterCard, American Express, Discover, PayPal and Apple Pay.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCurodont Repair at mydentist (UK) — from £140 per course
OtherPay-as-you-goDirect-to-consumer web shop on vvardis.com (US shipping only)

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

vVardis product offering

Product offering

Core offering

vVARDIS develops and commercializes its proprietary P11-4 biomimetic self-assembling peptide technology as the Curodont™ drill-free, needle-free chairside treatment for early-stage tooth decay. The peptide diffuses into early carious lesions, halts decay progression, and regenerates enamel by attracting calcium and phosphate from saliva — without drilling, anesthesia, or traditional filling materials. Products (Curodont Repair and Curodont Repair Fluoride Plus) are sold to dental professionals through Henry Schein (exclusive U.S. distributor) and channel partners, and oral care products are sold directly to consumers via vvardis.com.

Product overview

vVARDIS offers a single core technology platform — its proprietary P11-4 biomimetic peptide technology — which is commercialized through a unified product brand, Curodont™, comprising the chairside treatment Curodont Repair and the enhanced variant Curodont Repair Fluoride Plus. The Curodont family is the drill-free, needle-free treatment for early-stage dental caries and is delivered to dental professionals through the vVARDIS Professional program and the Certified Curodontist™ certification, supported by the "Save Teeth Save Lives" global awareness campaign. Together these elements form an integrated non-invasive dental-care platform rather than a set of unrelated products.

Differentiator

Problem solved

Functional benefit

Brands

  • Curodont: vVARDIS's proprietary biomimetic, peptide-based (P11-4) drill-free, needle-free dental treatment for early-stage tooth decay; includes Curodont Repair and Curodont Repair Fluoride Plus variants.
  • vVARDIS Professional

Products and services

  • Curodont Repair Chairside drill-free, needle-free treatment for early-stage tooth decay (caries) based on vVARDIS's proprietary P11-4 biomimetic self-assembling peptide. The peptide diffuses into early carious lesions, halts decay progression, and regenerates lost enamel minerals by attracting calcium and phosphate from saliva — without anesthesia, drilling, or traditional filling materials. Applied by dental professionals in as little as 3–10 minutes; suitable for children and adults.
  • Curodont Repair Fluoride Plus Enhanced chairside drill-free treatment combining vVARDIS's P11-4 biomimetic peptide technology with fluoride for early caries management. Used in same-day workflows following AI-powered caries detection by VideaHealth, with over 400,000 patients identified and treated with a 90%+ success rate. Sold to dental professionals in the US exclusively through Henry Schein across all dental segments including DSOs.

Quantifiable outcome

  • ~3 million teeth treated in the US since launch; ~20% of US general dental practices have adopted Curodont (April 2026)
  • +7 more outcomes

Companies that use vVardis

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

vVardis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature4 records

vVardis partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship / core, core and minor.

  • Henry Schein, Inc.flagship / coreChannel Partner/ Reseller/ Distributor · 1 December 2025Expanded partnership (announced December 1, 2025) makes Henry Schein the exclusive U.S. distributor of Curodont Repair Fluoride Plus across all U.S. dental segments starting January 1, 2026. Henry Schein had previously been named exclusive distributor to larger DSOs in September 2024. Henry Schein, Inc. is publicly traded on Nasdaq (HSIC), valued at approximately $9B with $12.7B in 2024 sales.
  • mydentistcoreChannel Partner/ Reseller/ Distributor · 1 November 2025First-of-its-kind partnership in UK dentistry announced January 2026 covering mydentist's network of ~500 practices; Curodont Repair offered at 100 practices from November 2025 with full network rollout from 2026. Priced from £140 per course, addressing more than four million patients in mydentist's network.
  • PearlcoreTechnology or Integration · 14 May 2025Global collaboration announced May 14, 2025, transforming early detection and proactive treatment of early dental decay. Pearl's AI enables dental practitioners to detect tooth decay earlier, while vVARDIS Curodont offers a drill-free solution to treat early stages of tooth decay.
  • VideaHealthflagship / coreTechnology or Integration · 13 June 2024Commercial collaboration combining VideaHealth's AI-powered dental detection (VideaAI) with vVARDIS's Curodont Repair Fluoride Plus for end-to-end early detection and drill-free treatment. Over 400,000 patients identified with early caries through VideaAI have been treated with Curodont, demonstrating 90%+ success rate in treating early caries.
  • Prestigious universities and dental schoolscoreStrategic or Co-development PartnervVARDIS partners with prestigious universities and dental professionals to advance research, support clinical studies, and progressively integrate Curodont technology into dental school curricula. The company's technology has been peer-reviewed in 230+ publications.
  • National Academy (sustainability in dentistry)minorStrategic or Co-development PartnervVARDIS products are included in the National Academy Training program focused on sustainability in dentistry, providing ESG-aligned training and education for dental professionals.
  • Heartland DentalcoreChannel Partner/ Reseller/ DistributorHeartland Dental (1,800+ practices across 39 states + DC) integrated advanced AI and biomimetic technologies including vVARDIS Curodont in 2024, expanding partnerships in 2025 as one of the major DSOs adopting Curodont across its supported practices.

Scale indicators11 records

Recent moves7 records

Expansion highlights8 records

vVardis competitors and assessment

Company assessment

Broad incumbents

  • Dentsply Sirona: Largest pure-play dental equipment and consumables company globally; supplies preventive and restorative materials (including fluoride, glass ionomers, and remineralization products) that compete for the same chairside minutes and DSOs as vVARDIS's Curodont. Comparable because it operates across the same dental practice and DSO buyer base, even though its biomimetic peptide exposure is limited.
  • 3M Oral Care (Solventum): Major dental materials and preventive care business (now part of Solventum) offering fluoride varnishes, sealants, and restorative products sold to the same U.S. dental practices and DSOs that vVARDIS targets. Comparable as a broad incumbent with overlapping preventive-care channels and the capital to bundle competing products.
  • GC Corporation: Japanese-headquartered dental materials manufacturer whose MI Paste / Recaldent (CPP-ACP) line is a competing chairside remineralization/early-caries product. Most directly comparable incumbent on the 'non-invasive early lesion treatment' category vVARDIS competes in.

Emerging players

  • Ultradent Products: U.S. dental materials manufacturer with a strong preventive and minimally invasive portfolio (e.g., enamel-strengthening and desensitizing products) sold to the same dental professionals as Curodont. Comparable as a specialist dental materials player competing for chairside early-intervention minutes.
  • VOCO: German dental materials company specializing in preventive and restorative products, including remineralization and sealants. Comparable to vVARDIS as a specialist competitor in early caries intervention and minimally invasive dental materials sold through professional channels.
  • BISCO: U.S. dental materials manufacturer focused on adhesive, resin, and preventive products sold to general dentists and specialists. Comparable as a specialist dental materials company competing for chairside early-intervention share and DSO contracts.
  • DMG Dental: German dental materials manufacturer with a portfolio including preventive and minimally invasive products sold to dental professionals globally. Comparable to vVARDIS in its focus on preventive/minimally invasive dentistry and DSO-relevant professional channels.
  • Premier Dental: U.S. dental products company offering preventive, restorative and hygiene products to general dentists and DSOs. Comparable as a specialist dental materials company with overlapping buyer base and product categories (prevention, remineralization).
  • Pearl (Pearl AI): AI dental imaging company with Second Opinion / Pearl AI detection software that flags early caries on dental x-rays — a current vVARDIS commercial partner. Comparable as a participant in the AI-powered early caries detection workflow that feeds Curodont treatments.
  • VideaHealth: AI dental caries detection company (VideaAI) that is a commercial partner with vVARDIS, having routed 400,000+ patients into Curodont treatment. Comparable as a participant in the same AI-detection-to-treatment workflow that drives vVARDIS's same-day chairside adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

vVardis social profiles

Digital presence

vVardis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

vVardis leadership team

Management profile

Number of profiles

Profiles4 records

vVardis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

vVardis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

vVardis M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about vVardis

What does vVardis do?

vVARDIS develops and commercializes its proprietary P11-4 biomimetic self-assembling peptide technology as the Curodont™ drill-free, needle-free chairside treatment for early-stage tooth decay. The peptide diffuses into early carious lesions, halts decay progression, and regenerates enamel by attracting calcium and phosphate from saliva — without drilling, anesthesia, or traditional filling materials. Products (Curodont Repair and Curodont Repair Fluoride Plus) are sold to dental professionals through Henry Schein (exclusive U.S. distributor) and channel partners, and oral care products are sold directly to consumers via vvardis.com.

Is vVardis a public or private company?

vVardis is a private company. It is classified as venture growth investor backed and is currently operating.

When was vVardis founded?

vVardis was founded in 2020. It employs 101 to 250 people.

Where is vVardis based?

vVardis is headquartered in Zug, Switzerland, in the Europe region.

How does vVardis make money?

Two revenue lines are on record. Dental professional / clinic product sales (via distribution partner) is the primary driver. The others are direct e-commerce sales of consumer oral care products.

Who are vVardis's main competitors?

Broad incumbents on record are Dentsply Sirona, 3M Oral Care (Solventum) and GC Corporation. Emerging players are Ultradent Products, VOCO, BISCO, DMG Dental, Premier Dental, Pearl (Pearl AI) and VideaHealth.

Does vVardis have an API?

No public API is recorded for vVardis.

What industry is vVardis in?

vVardis's product category is Biomimetic Dental Care. Its primary akta.pro industry code is HLABAAAC, Cosmetic & Esthetic Dentistry (Veneers/Whitening/Bonding), with a secondary code of HLABAHAJ, Non-Surgical Periodontal Therapy (Scaling & Root Planing). Its NAICS code is 339114 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NzzAbivardi-Schwestern: Von der Flucht aus Iran zur Wall StreetHaley and Goly Abivardi took their dental startup Vvardis to the New York Stock Exchange this week. The stock opened at $16.50, down from a $21-24 range, after Apollo's investment. The FDA has not reviewed the product's safety or efficacy.YahooHas vVARDIS Holding (VVVV) Fallen Enough to Sit Below Fair Value?vVARDIS Holding's stock has fallen 8.3% year to date, trading at $16.50, with no P/B disclosed. The company raised about $175 million in its IPO, and its valuation hinges on how quickly drill-free dental treatment becomes a durable franchise.YahoovVARDIS Holding (VVVV) Debuts Below Its IPO Price, Is The Pullback Already Justified?vVARDIS Holding debuted at $18 per share, trading down 8.33% to about $16.50 in its first session. The company also filed a $76.1 million shelf registration. No revenue or earnings data is available, so valuation anchors are missing.YahooWhat Does vVARDIS Holding (VVVV) Listing Mean For Its Drill Free Dental Push?vVARDIS Holding listed on the NYSE and raised $175 million in its IPO to fund expansion of its drill-free cavity treatment. The company's product has been used on over 2.5 million teeth and is present in more than 20% of US dental practices. Investors are advised to watch adoption metrics and executive compensation.Laotian TimesThe NYSE Welcomes vVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, went public on the NYSE under ticker VVVV. Its Curodont Repair Fluoride Plus product uses peptide technology to treat early tooth decay without drills, needles, or fillings. The treatment has already repaired over 2.5 million teeth and is available in more than 20% of U.S. dental practices.PR Newswire APACThe NYSE Welcomes vVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, is listed on the NYSE under ticker VVVV. Its Curodont product uses peptide technology to repair early tooth decay without drills or fillings, having treated over 2.5 million teeth and been available in more than 20% of U.S. dental practices.TradingViewThe NYSE Welcomes vVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, is listed on the NYSE. Its flagship product Curodont Repair Fluoride Plus uses peptide technology to treat early tooth decay without drills or fillings, having treated over 2.5 million teeth and been available in more than 20% of U.S. dental practices.AktienThe NYSE Welcomes vVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, is listed on the NYSE under the ticker VVVV. Its flagship product, Curodont Repair Fluoride Plus, uses peptide technology to treat early tooth decay without drills or fillings, having treated over 2.5 million teeth and been available in more than 20% of U.S. dental practices.MoomooThe NYSE Welcomes VVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, is publicly listed on the NYSE. Its Curodont Repair Fluoride Plus product uses peptide technology to treat early tooth decay without drills or fillings, having treated over 2.5 million teeth and been available in more than 20% of U.S. dental practices.NewswireThe NYSE Welcomes vVARDIS as a Publicly Listed CompanyvVARDIS, a Swiss dental technology company, is publicly listed on the NYSE. Its Curodont Repair Fluoride Plus product uses peptide technology to treat early tooth decay without drills or fillings, having treated over 2.5 million teeth and been available in more than 20% of U.S. dental practices.